Related Experiment Video
Updated: May 24, 2026
06:11
Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
Published on: February 9, 2022
Bronchodilator response in patients with normal baseline spirometry
Matthew J Hegewald1, Ryan G Townsend, Jaron T Abbott
1Division of Pulmonary and Critical Care Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. mhegewald@scmc.org
Respiratory Care
|March 16, 2012
Summary
A positive bronchodilator response in patients with normal spirometry is rare, occurring in 3.1% of cases. Bronchodilator testing may be unnecessary for individuals with normal spirometry and an FEV1 above 90% of predicted.
Area of Science:
- Pulmonary Medicine
- Respiratory Physiology
Background:
- Spirometry assesses airflow limitation reversibility via bronchodilator response.
- The frequency of positive bronchodilator response in patients with normal baseline spirometry is not well-described.
Purpose of the Study:
- To determine the frequency of positive bronchodilator response in adults with normal baseline spirometry.
- To identify demographic factors associated with a positive bronchodilator response in this population.
Main Methods:
- Retrospective analysis of adult patients from two academic pulmonary function testing labs over seven years.
- Included patients with normal baseline spirometry (FEV1, FVC, FEV1/FVC within normal limits).
- Calculated frequency of positive bronchodilator response (12% and 200 mL increase in FEV1 or FVC) and analyzed demographic associations.
Main Results:
- 3.1% (43 of 1,394) of patients with normal spirometry showed a positive bronchodilator response.
- Response rates varied by pre-bronchodilator FEV1: 6.9% for > lower limit of normal to 90% predicted, 1.9% for 90-100% predicted, and 0% for >100% predicted.
- Lower FEV1/FVC quartiles and older age were associated with a higher frequency of response.
Conclusions:
- The frequency of a positive bronchodilator response in patients with normal baseline spirometry is 3.1%.
- Patients with normal spirometry and FEV1 >90% predicted have a low probability of a positive response.
- Bronchodilator testing can potentially be omitted in patients with normal spirometry and FEV1 >90% predicted.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:25Pulmonary Function Tests
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.